Maria Sabanes-Vidal
Lleida, CT 25198, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Multiplexed CRISPR/Cas9 Editing of Tumor Suppressor Genes in the Mouse Endometrium Recapitulates High-Risk Endometrial Carcinoma.
Journal: Cancer communications (London, England)
Published: November 04, 2025
miR-424(322)~503 impairs colon cancer progression driven by PTEN deficiency.
Journal: Cell death & disease
Published: August 21, 2025
Endometrial cancer progression driven by PTEN-deficiency requires miR-424(322)~503.
Journal: Cell death & disease
Published: April 11, 2025
Metformin exhibits antineoplastic effects on Pten-deficient endometrial cancer by interfering with TGF-β and p38/ERK MAPK signalling.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 12, 2023
In Vivo Intra-Uterine Delivery of TAT-Fused Cre Recombinase and CRISPR/Cas9 Editing System in Mice Unveil Histopathology of Pten/p53-Deficient Endometrial Cancers.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: May 15, 2023
Transient and DNA-free in vivo CRISPR/Cas9 genome editing for flexible modeling of endometrial carcinogenesis.
Journal: Cancer communications (London, England)
Published: September 13, 2022
Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation.
Journal: Cancers
Published: July 20, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026